Products

MergeQuest

Stay on top of your GitLab merge requests

mergequest.app App StoreSoftware Development / Developer Utilities

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Pascal Bourque
@bourquep· 232 followers
Launched
2y ago
2023-12-27 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
X accounts@bourquep
  • Launched on Product HuntLaunch

    Stay on top of your GitLab merge requests

    Dec 27, 2023 · 2y agoLaunch page

Store data

App Store
App Store App Store
Update date not synced
Rating
Rating not syncedRating count not synced
New ratings last mo
—
Price & IAP
FreeIAP data not synced
Current version
—Store metadata

Store assets, rating histograms, install tiers, and screenshots are synced from Apple App Store, Google Play, and Chrome Web Store.

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered Unknown

KeywordMonthly volume
mergequest170

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2023-12-27

Key pages

Weekly snapshots
Home
mergequest.app/ Snapshot 2026-11-09

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does MergeQuest get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is MergeQuest and what platforms does it support?
MergeQuest is catalogued under Developer Utilities: Stay on top of your GitLab merge requests. Supported platforms: Mobile App.

Related products in this category

Software Development / Developer Utilities

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.